tbuckley/cabot-search huggingface dataset:
Medicaid
Authors: John K. Iglehart
Journal: New England Journal of Medicine (1993)

Medicaid, a health insurance safety net that shortchanges providers and bedevils its federal and state stewards because of its soaring expenditures, is nevertheless the financial lifeline of 28.3 million people who rely on it to pay for their medical and long-term care. As this sixth report on the American health care system16 describes, Medicaid purchases services for low-income people who are elderly, blind, disabled, or receiving Aid to Families with Dependent Children -- all groups that fall outside the employment-based insurance system. The Medicaid program accounts for about 16.5 percent of personal health spending in the United States. Whether . . .
OP0046 A risk score to identify individuals at higher risk of inflammatory polyarthritis: Results from the european prospective investigation of cancer (norfolk) and the norfolk arthritis register (the EPIC-2-NOAR study):
Authors: M. Lahiri, C. Morgan, R.N. Luben, D.K. Bunn, M. Lunt, S.M. Verstappen, D.P. Symmons, K.-T. Khaw, N.J. Wareham, I.N. Bruce
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Lifestyle factors can help us identify a cohort "at risk" of RA for further targeted genetic and serological screening for possible primary prevention. <h3>Objectives</h3> To develop a prediction score for individual risk of developing inflammatory polyarthritis (IP) and rheumatoid arthritis (RA) using easily ascertained demographic and lifestyle factors available to primary care and general physicians. <h3>Methods</h3> Lifestyle data were obtained from a prospective population-based study, the European Prospective Investigation of Cancer in Norfolk (EPIC-Norfolk) between 1994 and 1997. Individuals who subsequently developed IP were identified by linkage with the Norfolk Arthritis Register (NOAR), a primary-care based disease register with an overlapping catchment area. The primary outcome was development of IP. A Cox proportional hazards model was developed. A score was assigned to each risk factor based on the β-coefficients from the model (with negative scores for protective factors). The odds of developing IP based on the score were calculated by logistic regression. <h3>Results</h3> 25,455 EPIC participants aged 40-79 years were followed for a median (IQR) of 14.2 (12.9, 15.3) years (342,916 person-years of follow-up). 184 developed incident IP (69.6% women). The 10-year cumulative incidence of IP was 0.37% in men and 0.67% in women. For men, every 10 pack-years of smoking, being obese and having diabetes mellitus scored positively, whereas drinking up to 3 units of alcohol per day, and being of a higher occupational class scored negatively (Table, Area under the ROC curve 0.59). For women, smoking status was a better predictor than pack-years smoked and additional positive scores were assigned for having 2 or more children, whereas negative scores were assigned for every 6 months of breastfeeding (Table, area under the ROC curve 0.66). 1159 (8.4%) women had scores that reflect at least a 2% 10-year risk of IP which is &gt;3 times the risk of those with a score of 0. <h3>Conclusions</h3> Our scoring system, based on simply ascertained clinical and lifestyle factors can identify individuals at higher risk for IP. This will help focus enhanced serological and genetic screening in the population and aid in implementing preventative strategies against IP. <h3>Disclosure of Interest</h3> None Declared
Laparoscopic surgery
Journal: Gut (1994)

3rd UEGWOslo 1994 A165 was no significant difference among them.Time limits of these models were about 12-30 months.It seems giving better idea about liver functional state in cirrhosis within the limits.Correlating these models with Child classifica- tion, percentage of tally was 60-80%.But the effect of Child was not so good as the ones of B1 and B2.If Choosing 12, 18, 24, 30 and 36 months individually as effective limit, correctness of assessment of B1 and B2 were 68.57%, 67.86%, 88.77%, 75% and 78.26% in their given order and Child's were 51.43%, 46.53%, 50%, 45.83% and 52.17%.In terms of the effect above, B1 and B2 seemed more strict than Al and A2.A1 was the loosest of the four.It showed that it was better to use quan- tified numerical value than to use original numerical value in developing the new models for predicating prognosis of cirrhosis.In conclusion, the developed models showed the following characters:simple, practical and more effective.The models can be recommended to General/Family Doctors.But an ideal one needs further exploration.
Gustatory Rhinorrhea
Authors: Hobart, A. Reimann
Journal: JAMA (1967)

<h3>To the Editor:—</h3> (crocodile tears)<sup>1</sup>while eating and gustatory sweating (<b>201</b>:203, 1967) have been described. In most instances, the abnormal secretions began after injury from an infection, a surgical operation, or cranial trauma that affected nerves which control the responses. Theoretically, there is a misdirection of some collaterals of axons of nerve fibers innervating the lacrimal glands. In familial gustatory sweating without evidence of previous injury, an aberrent neuronal connection in the brain stem between the salivary
Reply
Authors: James Nelson, Kris Kowdley
Journal: Hepatology (2011)

We would like to thank Manco and colleagues for their interest in our article.1 We agree that stratification of our study cohort according the presence of diabetes and HFE (hereditary hemochromatosis) genotype status could be of interest. We have conducted additional analyses with regard to diabetes status in our cohort. HFE genotyping was not routinely performed as part of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Database study; this is currently in progress in an ancillary study. Among the 849 adult subjects in our study, 221 were enrolled in the PIVENS (Pioglitazone or Vitamin E for NASH Study) clinical trial,2 which excluded diabetic patients; therefore, to prevent any potential bias, we report here the relationship of diabetes and iron deposition in the remaining 628 subjects. As shown in Table 1, diabetic NASH CRN subjects were less likely to have hepatic iron deposition. In particular, diabetic patients had significantly less hepatocellular but not reticuloendothelial system iron deposition. There are several possible explanations for these findings. The iron regulatory hormone hepcidin is expressed in adipose tissue and has been shown to correlate to body mass index.3 It is possible that increased visceral fat in our diabetic subjects could lead to greater circulating hepcidin levels, reduced iron absorption, and less hepatocellular iron deposition. Recently, alcohol has been shown to down-regulate hepcidin gene expression.4 Because diabetic subjects in our study consumed less alcohol than subjects without diabetes, this could also contribute to higher hepcidin levels in these patients. Diabetic subjects were also more likely to be women, and physiologic blood loss through menstruation and childbirth may have resulted in decreased body iron stores. Additional studies are warranted to define the mechanism for decreased hepatocellular iron content in diabetic patients with NAFLD. In contrast to Manco et al.,5 who have reported hepatic iron deposition in 29% of their Italian pediatric subjects, which was not associated with measurements of insulin resistance, the prevalence of iron deposition in the NASH CRN pediatric subjects was only 4%. It is likely that, as in adults, differences in the Italian and U.S. cohorts, including body mass index (25.2 in Manco et al. versus 33.0 in the NASH CRN pediatric subjects) account for the observed differences.6 James Nelson Ph.D.*, Kris Kowdley M.D.*, * Benaroya Research Institute, Virginia Mason Medical Center, Seattle, WA.
European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) 2010 – call for abstracts
Authors: None Eurosurveillance editorial team
Journal: Eurosurveillance (2010)

Preview this article: European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE) 2010 – call for abstracts, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/15/25/art19596-en-1.gif
Reply
Authors: T. Hashimoto
Journal: British Journal of Dermatology (1988)

Journal Article Reply Get access T. Hashimoto T. Hashimoto Section of Dermatology, The Kitasato Institute Hospital Tokyo 108, Japan Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 118, Issue 4, 1 April 1988, Page 586, https://doi.org/10.1111/j.1365-2133.1988.tb02477.x Published: 01 April 1988
Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study
Authors: J. Geisler
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To compare the effects of the two novel, potent, nonsteroidal aromatase inhibitors anastrozole and letrozole on total-body aromatization and plasma estrogen levels. PATIENTS AND METHODS: Twelve postmenopausal women with estrogen receptor–positive, metastatic breast cancer were treated with anastrozole 1 mg orally (PO) and letrozole 2.5 mg PO once daily, each given for a time interval of 6 weeks in a randomized sequence. Total-body aromatization was determined before treatment and at the end of each treatment period using a dual-label isotopic technique involving isolation of the metabolites with high-performance liquid chromatography. Plasma levels of estrone (E1), estradiol (E2), and estrone sulfate (E1S) were determined in samples obtained before each injection using highly sensitive radioimmunoassays. RESULTS: Pretreatment aromatase levels ranged from 1.68% to 4.27%. On-treatment levels of aromatase were detectable in 11 of 12 patients during treatment with anastrozole (mean percentage inhibition in the whole group, 97.3%) but in none of the 12 patients during treatment with letrozole (> 99.1% suppression in all patients; Wilcoxon, P = .0022, comparing the two drug regimens). Treatment with anastrozole suppressed plasma levels of E1, E2, and E1S by a mean of 81.0%, 84.9%, and 93.5%, respectrively, whereas treatment with letrozole caused a corresponding decrease of 84.3%, 87.8% and 98.0%, respectively. The suppression of E1 and E1S was found to be significantly better during treatment with letrozole compared with anastrozole (P = .019 and .0037, respectively). CONCLUSION: This study revealed letrozole (2.5 mg once daily) to be a more potent suppressor of total-body aromatization and plasma estrogen levels compared with anastrozole (1 mg once daily) in postmenopausal women with metastatic breast cancer.
Diabetes
Authors: A. R. Colwell
Journal: JAMA (1969)

The report is packed with current clinical and biochemical findings contributed in Stockholm by more than 200 workers expert in the field. Most articles present results of many years' work, include generous numbers of good-sized figures and electron photomicrographs, and contain special references. Some provide general but concise and well-founded observations by practitioners; others, detailed analyses of interest only to other biochemists. To facilitate international research planning, the major symposia on the program dealt with controversial subjects such as insulin-like activity, angiopathy, insulin action, and resistance. Several erudite papers are gathered in each group, and introduced with comments by the moderator. The gamut of basic investigation begins with the evolution of islet tissue and comparative immunology of insulin, and ends with the recent synthesis of A and B chains by Katsoyannis and Zahn. The remaining articles describe the current status of studies following different lines of pathogenesis. Diabetes is a
CARDIAC STANDSTILL WITH SYNCOPE FOLLOWING PRESSURE ON RIGHT VAGUS NERVE
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang, Weidong Han
Journal: Journal of Hematology & Oncology (2020)

An amendment to this paper has been published and can be accessed via the original article.
AN EDITORIAL OVERSIGHT.
Journal: JAMA (1899)

In its issue of August 5, the<i>N. Y. Medical Record</i>editorially gives credit to the American author, Dr. Leonard Corning, for priority in the method of local anesthesia by intraspinal injection, a method lately rediscovered by Bier of Keil, and published by him in the<i>Deutsche Zeitsch. f. Chir.</i>last April. The recognition is an excellent thing and the editorial prominence given it by the editor of the<i>Record</i>is altogether admirable, but it comes a little late. If he had thoroughly perused an up-to-date journal and read Dr. Matas' review of the progress of surgery in our souvenir issue of June 3, he might have given it in his editorial on June 24, on "A New Method of Anesthesia." Not only was Corning's work noticed in Dr. Matas' paper above, but also the fact that it antedated the "so-called methods of Oberst and of Bier." We are not
Too Much Thyroid Hormone Increases Risk for Bone Fractures
Journal: Annals of Internal Medicine (2001)

Summaries for Patients3 April 2001Too Much Thyroid Hormone Increases Risk for Bone FracturesSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-7-200104030-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?As people get older, their bones lose calcium and become less dense. When this bone thinning becomes severe, it is called osteoporosis. Persons with osteoporosis are at high risk for broken bones (fractures). Many older women have osteoporosis. Some older women also have problems with the thyroid gland, a gland located in the neck that makes thyroid hormone. Thyroid hormone is important in regulating the body's metabolism, particularly its use of energy, fats, and protein. Several past studies have examined whether high levels of thyroid hormone lead to ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Risk for Fracture in Women with Low Serum Levels of Thyroid-Stimulating Hormone.” It is in the 3 April 2001 issue of Annals of Internal Medicine (volume 134, pages 561-568). The authors are DC Bauer, B Ettinger, MC Nevitt, and KL Stone, for the Study of Osteoporotic Fractures Research Group.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk for Fracture in Women with Low Serum Levels of Thyroid-Stimulating Hormone Douglas C. Bauer , Bruce Ettinger , Michael C. Nevitt , Katie L. Stone , and Metrics 3 April 2001Volume 134, Issue 7Page: I-85KeywordsBoneBone fractureHip fracturesOsteoporosisProtein metabolismRisk managementSpineThyroidThyroid hormonesThyroid-stimulating hormone ePublished: 3 April 2001 Issue Published: 3 April 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Cytarabine treatment of progressive multifocal leukoencephalopathy. Clinical course and detection of virus-like particles after antiviral chemotherapy
Authors: J. P. Conomy
Journal: JAMA (1974)

Cytarabine (cytosine arabinoside) was utilized in the treatment of a patient with chronic lymphocytic leukemia who developed symptomatic progressive multifocal leukoencephalopathy (PML) after a 12-year course of lymphoproliferative illness. An immediate and impressive degree of neurologic improvement occurred with the institution of antiviral chemotherapy, but clinical benefit was not sustained and the patient died of his neurologic disorder. On gross examination at postmortem, necrotic changes in the demyelinated areas of the brain were seen. Light and electron microscopic studies showed changes characteristic of PML and virus-like particles abundant in glial cells. Cytarabine may have some influence on the course of the illness, but the quality of therapeutic effect needs further investigation. (<i>JAMA</i>229:1313-1316, 1974)
Breast cancer drug adrenalectomy 'passes'
Authors: J. Henahan
Journal: JAMA (1984)

In the largest trial of its type carried out so far, the drug aminoglutethimide, which accomplishes a medical adrenalectomy, continues to appear to be effective for the treatment of postmenopausal women with disseminated breast cancer. Aminoglutethimide acts by inhibiting the enzymatic conversion of cholesterol to pregnenolone, an essential precursor of all steroid hormones. It has also been shown to inhibit the aromatase enzymes necessary for synthesis of estrogens from steroid precursors, thereby inhibiting estrogen synthesis in postmenopausal women. When 305 women with advanced breast cancer were given aminoglutethimide, the overall response rate was 26.5%, according to Trevor Powles, MB, Royal Marsden Hospital, Surrey, England. In 3.6% (11 patients), all evidence of disease disappeared (complete response), and in 22.9% (70 patients), some evidence of disease disappeared (partial response). The disease was stabilized in another 12.7% (40 patients). "The median duration of response was 14 months and was the same whether patients
The Propaganda for Reform
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Crystalluria Potential of Cholecystographic Agents
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Queries and Minor Notes
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outbreak of Community-Acquired Pneumonia Caused by Mycoplasma pneumoniae--Colorado, 2000
Journal: JAMA (2001)

On May 18, 2000, the Colorado Department of Public Health and Environment (CDPHE) was contacted by a family physician in Moffat County, Colorado (1998 population: 12,700), about a large number (>50) of community-acquired pneumonia cases diagnosed by chest radiograph in a group practice over several months. An investigation by state public health officials and CDC implicated Mycoplasma pneumoniae as the cause of illness. This report summarizes the results of the investigation and underscores the importance of investigating outbreaks of severe unexplained respiratory illness to enable implementation of appropriate treatment and control measures.